
What We’re Reading: Boosters Slash COVID-19 Deaths; Generic Restasis Cleared; Medicare Advantage and Health Equity
Americans who are boosted are 95 times less likely than unvaccinated people to die of COVID-19, the FDA approved the first generic drug for Restasis to treat dry eye syndrome, and CMS is putting a greater focus on health equity for Medicare Advantage and Part D plans.
Boosted Americans 95 Times Less Likely to Die of COVID-19
According to
FDA Approves First Generic for Restasis
The FDA approved the first generic version of AbbVie’s Restasis (cyclosporine ophthalmic emulsion), a drug used to increase tear production in patients with dry-eye syndrome, as reported by
CMS Puts Focus on Health Equity in Medicare Plans
The 2023 annual rule for Medicare Advantage and Part D plans is going to have a focus on health equity, according to
Related to this article








